Neutrophils as a marker of response to chemo-immunotherapy in lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study is testing whether certain white blood cells (called neutrophils) in your tumor can predict how well a combination of chemotherapy and immunotherapy works before surgery for lung cancer. If you qualify, you would receive this treatment and then have surgery, and researchers would track your response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a type of lung cancer called non-small cell lung cancer (NSCLC) that is at a stage where it can be surgically removed (stage IIA to IIIB).
- You have no cancer spread to the brain or other organs outside the chest (confirmed by imaging).
- You are healthy enough for surgery, and your lung function is good enough for the operation.
- You have not had prior chemotherapy or immunotherapy for this same lung cancer.
- You are not pregnant and can participate in a research study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This trial tests whether certain markers in your blood or tissue can predict how well immunotherapy works before surgery for early-stage lung cancer. It aims to find out who benefits most from this treatment.
This study looks at a new blood test to predict how well standard-of-care chemotherapy plus immunotherapy works for people with advanced non-small cell lung cancer. It aims to personalize treatment by identifying patients who may benefit most, potentially improving outcomes and reducing unnecessary side effects.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This study tests whether doing surgery only after checking if the tumor shrinks with chemo-immunotherapy is safe and effective for people with locally advanced lung cancer. It may help avoid surgery if the cancer hasn't responded well.
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.